source
- Gossamer Bio regains rights to lung disease asset from Chiesi after Phase 3 failure, eyes FDA submissionGossamer Bio announced that it has taken back the rights to its inhaled pulmonary hypertension candidate from partner Chiesi after the drug failed to meet its primary endpoint in a Phase 3 trial.…
- Study shows drug development and reimbursement timelines align across four major marketsResearchers published a cross‑sectional analysis in JAMA Health Forum examining how long it takes for a drug to move from the start of clinical trials to receiving reimbursement approval. The anal…